{"id":"alt-100","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297259","moleculeType":"Small molecule","molecularWeight":"226.18"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"While specific mechanistic details for ALT-100 are limited in public literature, the drug is being developed by Aqualung Therapeutics as an immunotherapeutic agent. Given its phase 2 status and the company's focus, it likely works through immune checkpoint modulation or T-cell engineering approaches to enhance anti-tumor or anti-disease immune responses.","oneSentence":"ALT-100 is an investigational immunotherapy designed to modulate immune responses, likely through targeting specific immune checkpoints or enhancing T-cell activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:08:21.275Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05938036","phase":"PHASE2","title":"Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aqualung Therapeutics Corp.","startDate":"2023-12-01","conditions":"Acute Respiratory Distress Syndrome (ARDS)","enrollment":15},{"nctId":"NCT05426746","phase":"PHASE1","title":"First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100","status":"COMPLETED","sponsor":"Aqualung Therapeutics Corp.","startDate":"2022-07-05","conditions":"ARDS, Human","enrollment":32},{"nctId":"NCT03681132","phase":"PHASE4","title":"The Norwegian Nucleoside Analogue Stop Study","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2018-09-20","conditions":"Hepatitis B, Chronic","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ALT-100","genericName":"ALT-100","companyName":"Aqualung Therapeutics Corp.","companyId":"aqualung-therapeutics-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}